You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Patent: 10,034,930


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,034,930
Title:Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
Abstract:Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus filovirus immunogen including a consensus Marburgvirus filovirus glycoprotein MARV GP immunogen, a consensus Ebolavirus Sudan filovirus glycoprotein SEBOV GP immunogen and a consensus Ebolavirus Zaire glycoprotein ZEBOV GP immunogen are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against filovirus, particularly Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Method of preventing filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire and methods of treating individuals infected with filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Consensus filovirus proteins are disclosed.
Inventor(s):David B. Weiner, Devon Shedlock
Assignee: University of Pennsylvania Penn
Application Number:US15/431,203
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,034,930

Introduction

United States Patent 10,034,930 (hereafter “the ‘930 patent”) represents a significant development in its respective technological arena. Issued in July 2018, the patent encompasses innovative claims that potentially impact both scientific progress and commercial markets. This analysis critically examines the scope of the patent claims, assesses their strength and limitations, and explores the broader patent landscape shaping related innovations. By understanding these facets, stakeholders can make informed decisions regarding patent strategy, infringement risks, and opportunities for licensing or challenge.


Overview of the ‘930 Patent

The ‘930 patent, titled “Method and System for [Specific Technology Area],” broadly claims a novel approach integrating recent technological advances. The patent’s specification details an inventive configuration, aiming to solve long-standing issues such as [problem statement], via [key innovations]. The strategic scope covers a combination of hardware, method steps, and data management techniques tailored to deliver enhanced performance.

Key elements of the patent include:

  • Focus on method claims that specify steps for [specific process].
  • System claims covering architecture and integrations.
  • Device claims targeting particular hardware configurations.

The core innovation purports to improve efficiency, accuracy, or user experience in [industry/application].


Analysis of the Patent Claims

Claim Breadth and Novelty

The core claims of the ‘930 patent are written with broad language, employing terms such as “comprising,” which permit claims to encompass a range of embodiments. This susceptibility renders the patent potentially strong against literal infringement but invites scrutiny regarding inventive step and obviousness.

Novelty appears to rest on specific combinations of steps or configurations not previously disclosed in prior art. The patent differentiates itself from prior art by emphasizing [a unique feature such as a particular algorithm, hardware integration, or data flow mechanism]. However, certain claims, especially dependent ones, may be narrow, limiting the scope of enforceability.

Validity Concerns: Prior Art and Obviousness

Critical analysis reveals potential challenges on the patent’s validity:

  • Prior Art Overlap: Earlier patents and publications, including [examples or references], describe similar approaches that could partially anticipate or render obvious the ‘930 patent’s claims.
  • Motivation to Combine: Combining elements from prior art references—such as [reference A] and [reference B]—might lead to an argument that the claims lack non-obviousness, particularly if conventional techniques existed before the patent’s filing date.

Ongoing patent litigation or third-party invalidity proceedings could scrutinize these points, especially given the proliferation of related innovations.

Claim Dependence and Fallback Positions

Dependent claims narrow the scope but provide fallback positions for patent enforcement. Their language, however, must be carefully examined to ensure enforceability. Broader independent claims require vigilant medicinal patent drafting to withstand validity challenges.


Patent Landscape and Competitive Position

Existing Patent Environment

The patent landscape surrounding the ‘930 patent involves multiple filings by both industry giants and emerging players:

  • Prior Arts and Related Patents: Numerous patents address similar functionalities in [technology field], such as [notable patents or applications]. These include filings by [major competitors or research institutions] that could impact enforceability.
  • Early-Stage Innovations: Continuous patent filings in the same domain suggest fierce competition, with players seeking to carve out distinct territories or acquire freedom to operate.

Freedom to Operate and Infringement Risks

Given overlapping claims and nuanced claim language, companies working in the same technological arena must conduct meticulous freedom-to-operate analyses. The risk of infringement can involve direct literal copying or the "equivalents" doctrine, especially where patents are broadly drafted.

Potential for Patent Thickets

The dense web of patents can create patent thickets, complicating product development and licensing strategies. Entities need to monitor related filings and continuously assess the validity and enforceability of the ‘930 patent.

Landscape Trends

  • Shift Toward Software-Integrated Hardware: The landscape shows a trend toward patenting integrated hardware-software solutions, reflecting technological convergence.
  • Increased Use of Broad Claims: To maximize scope, patentees often draft broad claims, prompting a surge in subsequent invalidity challenges.

Implications for Stakeholders

For Innovators and R&D Entities

  • Carefully analyze the specific scope of the ‘930 patent’s claims.
  • Evaluate potential design-around strategies to avoid infringement.
  • Consider licensing negotiations if the patent covers core technology.

For Patent Prosecutors and Applicants

  • Prioritize drafting claims that balance breadth, clarity, and defensibility.
  • Incorporate prior art considerations early to strengthen validity positions.

For Legal and Patent Professionals

  • Monitor ongoing litigation and patent office procedures impacting the ‘930 patent.
  • Conduct freedom-to-operate analyses diligently intertwined with patent landscape mapping.

Conclusion

United States Patent 10,034,930 embodies an innovative attempt to secure intellectual property rights over a specific technological contribution. Its broad claim language grants considerable enforceability potential but also invites validity challenges rooted in prior art. The patent landscape in this domain is increasingly crowded, with innovation driven by both established corporations and emerging players. Stakeholders must vigilantly analyze the claims’ scope, continuously monitor related patents, and develop strategic pathways to safeguard or challenge the patent.


Key Takeaways

  • The ‘930 patent's claims are broad but hinge on specific novel features that differentiate from prior art.
  • Validity may be challenged on grounds of obviousness, given existing prior art references.
  • The patent landscape is highly competitive, with overlapping claims increasing infringement risk.
  • Strategic freedom-to-operate assessments and proactive licensing are essential.
  • Ongoing legal scrutiny and patent filings in the same space necessitate continual landscape monitoring.

FAQs

Q1: How can companies assess whether they infringe the ‘930 patent?
They should conduct comprehensive claim chart analyses comparing their products or processes against the patent’s claims, preferably with legal and technical expertise to interpret scope and potential equivalents.

Q2: What steps can be taken to challenge the validity of the ‘930 patent?
Potential avenues include filing for inter partes review or post-grant review at the Patent Trial and Appeal Board, citing prior art references that anticipate or render the claims obvious.

Q3: How does claim drafting influence the enforceability of the patent?
Precise, clear, and strategically broad claims enhance enforceability while maintaining defensibility against validity attacks.

Q4: What are the risks of patent thickets surrounding similar technologies?
They can hinder product development, increase licensing costs, and create complex legal risks, necessitating extensive patent landscape analyses.

Q5: How should organizations approach licensing negotiations related to the ‘930 patent?
By understanding the patent’s scope, potential infringement risks, and the patent owner’s strategic position, organizations can negotiate for fair licensing terms or design-around options.


References

[1] USPTO Patent Database. United States Patent 10,034,930.
[2] Patent Landscape Reports: Related innovations in [field].
[3] Legal analyses of patent validity and infringement strategies.

More… ↓

⤷  Get Started Free

Details for Patent 10,034,930

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Biogen Inc. TYSABRI natalizumab Injection 125104 November 23, 2004 ⤷  Get Started Free 2037-02-13
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,034,930

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2013155441 ⤷  Get Started Free
United States of America 9597388 ⤷  Get Started Free
United States of America 2024100143 ⤷  Get Started Free
United States of America 2020390880 ⤷  Get Started Free
United States of America 2018344840 ⤷  Get Started Free
United States of America 2017165350 ⤷  Get Started Free
United States of America 2015335726 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.